Novo nordisk a/s today
Novo Nordisk a/s.
- 52-week range
- $ 57.00
▼
$ 148.15
- Dividend yield
- 2.53%
- P/e ratio.
- 19.56
- Value is valuable
- $ 135.00
Despite the double blow to his Quarterly earnings on May 7Novo Nordisk a/s NYSE: NVO The shares still decreased by almost 50% in 2025. However Promotions are now traded next to the 52-week minimum And it is a discount for itself in several indicators. Analysts believe that NVO shares Significant potentialSo is it a purchase?
To answer this question, a realistic, long -term forecast is required. This is not what many investors love to hear. In the short term, some factors can cancel stocks and even send it below. However, if you are looking Value in unstable spaceNVO begins to have some appeal.
In the GLP-1 market it becomes noisy
Perhaps this is not a great week to hear your company product called a “fat shot”. But this is exactly what happened when President Trump announced his executive disposal, giving the United States the “most favorable” status of the nation in relation to Drug pricing policyField
This new executive order will affect many medical actions but, as they say, pays special attention to the drugs that have “the largest differences and largest expensesThis will probably include GLP-1 drugs. This also happened after the president had dinner with the Director General Eli Lilly & Co. NYSE: Lly In Mar-A-Lala. At that time, the General Director of Lilly David Ricks noted that the increase in medicines in other developed countries will be a key strategy to reduce costs in the United States.
New Nordisk is Headquarters -apartment in DenmarkThe company was the first to have the approved GLP-1 preparation for obesity in the market, and it has 72% market share In the GLP-1 space.
This means that Novo Nordisk may most of all lose two companies that make up duopoly in this market. New Nordisk is faced New oral preparation GLP-1 from Eli Lilly, was more effective than the new Nordisk RybelsusField
Rybelsus is currently approved only for the treatment of type 2 diabetes (T2D). Novo Nordisk has applied for the oral version of Wegovy, which FDA It is expected that he will approve the end of the year.
However, Novo Nordisk leaves nothing in case. The company signed 2.2 billion dollars of transaction With septter NASDAQ: SEPNBoth companies will jointly develop up to four new oral small molecular methods of treatment, one of which will be aimed at obesity.
The new CVS transaction adds intrigue to the situation
In early May, CVS Health Corp. NYSE: CVS announced that it would Remove Zepbound from its standard shape on June 1, 2025Continuing to offer only Wegovy for the treatment of losing weight. CVS Health owns the largest Pharmacy manual management (PBM) Business in the United States.
In her income report, Novo Nordisk Management stated that she was not suitable for CVS about exclusivity. It was an independent CVS solution.
NVO shares, by the visible, are underestimated
WITH Advanced ratio of price for profit (p/e) around 17xNovo Nordisk is traded at a discount on its average indicator for twelve -month (TTM), as well as with average values with three and five -year -olds. The same applies to the company Sale price (p/s) And Book price coefficients (p/b)Field
Novo nordisk a/s Promotion forecast today
$ 135.00
109.81% growthHold
Based on 13 analysts ratings
| The current price | $ 64.35 |
|---|---|
| High forecast | $ 160.00 |
| Average forecast | $ 135.00 |
| Low forecast | $ 64.00 |
Novo nordisk a/s Promotion forecast
Then there is an opinion of analysts. NOVO Nordisk Analyst Predictions on Marketbeat show Consensus holds the ratingField
A Price price of $ 135 is 108% of growth from the current level of action and will change most of it Reduced over the past 12 months.
However, as of May 14, 2025, NVO shares did not restore their 50-day simple sliding average at a speed of about 70 US dollarsThis field happened as a resistance point last year. Nevertheless, shares have decreased only by about 1.5% over the past month, despite a sharp increase in a short percentage.
Despite a low short volume compared to swimming, 31% of short interest growth For more than 30 days it signals about growing bear moods.
Before considering Novo Nordisk A/S, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before a wider market is won … and Novo Nordisk A/S was not on the list.
While Novo Nordisk A/S currently has a retention rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Want to make a profit from the mega-train electric car? Enter your email address, and we will send you our list from which EV shares show the most long -term potential.
Get this free report